SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-037602
Filing Date
2024-03-22
Accepted
2024-03-22 08:52:20
Documents
15
Period of Report
2024-03-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm249333d1_8k.htm   iXBRL 8-K 24665
2 EXHIBIT 99.1 tm249333d1_ex99-1.htm EX-99.1 65331
6 GRAPHIC tm249333d1_ex99-1img001.jpg GRAPHIC 12060
  Complete submission text file 0001104659-24-037602.txt   289793

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ckpt-20240322.xsd EX-101.SCH 3027
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ckpt-20240322_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ckpt-20240322_pre.xml EX-101.PRE 22367
18 EXTRACTED XBRL INSTANCE DOCUMENT tm249333d1_8k_htm.xml XML 3616
Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38128 | Film No.: 24773249
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)